Urothelial Carcinoma
Urothelial Carcinoma
Advertisement
Emily MenendezMuscle Invasive Urothelial Carcinoma | March 23, 2023
The RaDar assay tracks up to 48 tumor-specific variants in cell-free DNA in a cancer patient’s blood plasma.
Read More
Vignesh Packiam, MDNon-Muscle Invasive Urothelial Carcinoma | March 22, 2023
Vignesh T. Packiam, MD discusses the current BCG shortage as well as potential substitutes such as gemcitabine and docetaxel.
Sangeeta Goswami, MD, PhDUrothelial Carcinoma | March 21, 2023
Dr. Goswami discusses the trials that are changing our understanding of resistance to ICIs in kidney and bladder cancer.
Emily MenendezAdvanced Urothelial Carcinoma | March 17, 2023
The TITAN-TCC trial examined the safety and efficacy of nivolumab induction with ipilimumab as an immunotherapeutic boost.
Emily MenendezUpper Tract Urothelial Carcinoma | March 10, 2023
A team of researchers set out to determine the preferred sequence of perioperative systemic therapy for node-positive UTUC.
Rachelle Rodriguez, MS, APRN, AOCNPExpert Interviews | March 6, 2023
Rachelle Rodriguez, MS, APRN, AOCNP, highlights her role in helping Moffitt grow its APP presence within the GU onc program.
Emily MenendezNon-Muscle Invasive Urothelial Carcinoma | February 27, 2023
IFNα and nadofaragene firadenovec can provide a new therapy approach for a disease with a significant unmet clinical need.
Akhil Abraham Saji, MDNon-Muscle Invasive Urothelial Carcinoma | February 24, 2023
BCG plus nogapendekin alfa inbakicept may offer an enhanced treatment option for patients with high-risk NMIBC.
Daniel M. Geynisman, MDASCO GU Symposium 2023 | February 23, 2023
Daniel M. Geynisman, MD, explains the results and utility of the RETAIN trial for bladder sparing in patients with MIBC.
Oncology BrothersOncology Brothers | February 22, 2023
Petros Grivas, MD, PhD, highlights the practice-changing studies that have come out of the ASCO GU 2023 Symposium.
Andrea Necchi, MDASCO GU Symposium 2023 | February 18, 2023
Andrea Necchi, MD, speculates on the applicability of pembrolizumab monotherapy for BCG-unresponsive NMIBC.
Kyle M. Rose, MDASCO GU Symposium 2023 | February 18, 2023
Kyle M. Rose, MD, describes how cell-free DNA is used to detect MRD prior to repeat-transurethral resection in NMIBC.
Daniel P. Petrylak, MDASCO GU Symposium 2023 | February 18, 2023
Daniel P. Petrylak, MD, overviews the TROPHY-U-01 study for platinum-ineligible patients with metastatic UC.
Christine Ibilibor, MDASCO GU Symposium 2023 | February 17, 2023
Christine Ibilibor, MD, shares the race disparities in UC diagnoses and outcomes, as well as strategies to mitigate them.
Matthew D. Galsky, MDASCO GU Symposium 2023 | February 17, 2023
Matthew Galsky, MD, contextualizes HCRN GU 16-257 as a potential game-changer for bladder sparing in patients with MIBC.
Emily MenendezASCO GU Symposium 2023 | February 17, 2023
A study presented at the 2023 ASCO GU Cancers Symposium evaluated K17 expression in several forms of urothelial carcinoma.
Emily MenendezASCO GU Symposium 2023 | February 17, 2023
A research team sought to define the tumor protein co-expression of PD-L1, c-MET, and HER2 in a cohort of patients with mUC.
Zachary BessetteASCO GU Symposium 2023 | February 17, 2023
IAC-RT may be a useful and tolerable treatment option for patients with MIBC who are unfit for radical cystectomy.
Emily MenendezASCO GU Symposium 2023 | February 17, 2023
Researchers analyzed the impact of EV+P or EV alone on QOL and symptoms based on the EV-103 Cohort K trial.
Emily MenendezASCO GU Symposium 2023 | February 17, 2023
A recent study analyzed the effectiveness of BCG treatment in patients with NMIBC, including a subgroup of patients with CIS.
Advertisement
Advertisement
Advertisement